Skip to main navigation
Skip to search
Skip to main content
Rutgers, The State University of New Jersey Home
Help & FAQ
Link opens in a new tab
Search content at Rutgers, The State University of New Jersey
Home
Profiles
Research units
Core Facilities
Federal Grants
Research output
Comparative effectiveness research and the rise of orphan indications
Sarah Jeffers
, Mark Slomiany
, Rema Bitar
, Sarah Kruse
,
Mahmud Hassan
Rutgers Business School, Finance & Economics
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Comparative effectiveness research and the rise of orphan indications'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Comparative Effectiveness Research
100%
Orphan Indication
100%
Pharmaceutical Industry
66%
Orphan Drugs
50%
Reinvestment
33%
Affordable Care Act
33%
Drugs for Rare Diseases
33%
Pre-existing Conditions
16%
Healthcare
16%
Access to Care
16%
Medical Conditions
16%
Health Outcomes
16%
Drug Development
16%
Costing Methods
16%
Public Sector
16%
Rare Diseases
16%
Design Methodology
16%
Healthcare Expenditure
16%
Real Examples
16%
Role of Government
16%
Modern Approaches
16%
Rapid Rise
16%
Low Budget
16%
Implementation Process
16%
Effective Cost
16%
Affordable Care
16%
Small Patients
16%
Budget Impact
16%
Computer Science
Practical Implication
100%
Effective Method
100%
American Recovery and Reinvestment Act
100%
Medical Condition
100%
Modern Approach
100%
Social Implication
100%
Pharmacology, Toxicology and Pharmaceutical Science
Rare Disease
100%
Orphan Drug
100%
Base
33%
Drug Development
33%
Weakness
33%
Economics, Econometrics and Finance
Pharmaceutical Industry
100%
Reinvestment
50%
Private Sector
25%
Public Sector
25%
Price
25%